Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease

JAMA. 2022 Dec 13;328(22):2269-2271. doi: 10.1001/jama.2022.17485.
No abstract available

Plain language summary

This study examines the association of sublingual buprenorphine/naloxone and dental adverse events using the IQVIA health claims database.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Sublingual
  • Analgesics, Opioid* / administration & dosage
  • Analgesics, Opioid* / adverse effects
  • Analgesics, Opioid* / therapeutic use
  • Buprenorphine, Naloxone Drug Combination* / administration & dosage
  • Buprenorphine, Naloxone Drug Combination* / adverse effects
  • Buprenorphine, Naloxone Drug Combination* / therapeutic use
  • Humans
  • Narcotic Antagonists* / administration & dosage
  • Narcotic Antagonists* / adverse effects
  • Narcotic Antagonists* / therapeutic use
  • Opioid-Related Disorders* / drug therapy
  • Stomatognathic Diseases* / chemically induced

Substances

  • Analgesics, Opioid
  • Buprenorphine, Naloxone Drug Combination
  • Narcotic Antagonists